ROCÍO
GARCÍA CARBONERO
Profesora asociada de Ciencias de la Salud
KU Leuven
Lovaina, BélgicaPublicaciones en colaboración con investigadores/as de KU Leuven (21)
2023
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
The Lancet, Vol. 402, Núm. 10395, pp. 41-53
-
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study
The Lancet Oncology, Vol. 24, Núm. 2, pp. 187-194
2022
-
The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms
European Journal of Cancer, Vol. 168, pp. 80-90
2021
-
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 5, pp. 665-677
-
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
Annals of Oncology, Vol. 32, Núm. 5, pp. 600-608
2020
-
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials
Annals of Oncology, Vol. 31, Núm. 1, pp. 88-95
-
Pembrolizumab in microsatellite-instability-high advanced colorectal cancer
New England Journal of Medicine, Vol. 383, Núm. 23, pp. 2207-2218
2019
-
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
Annals of Oncology, Vol. 30, Núm. 1, pp. 124-131
-
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
Oncologist, Vol. 24, Núm. 2, pp. 185-192
2018
-
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
Annals of Oncology, Vol. 29, Núm. 3, pp. 602-609
-
Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: Exploratory analyses of the RAISE trial and validation in an electronic medical record data set
ESMO Open, Vol. 3, Núm. 3
-
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
Annals of Oncology, Vol. 29, Núm. 1, pp. 119-126
2017
-
Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial
Cancer Chemotherapy and Pharmacology, Vol. 80, Núm. 3, pp. 599-608
-
Proxies of quality of life in metastatic colorectal cancer: Analyses in the RECOURSE trial
ESMO Open, Vol. 2, Núm. 5
-
Randomized phase II trial of parsatuzumab (Anti-EGFL7) or placebo in combination with FOLFOX and bevacizumab for first-line metastatic colorectal cancer
Oncologist, Vol. 22, Núm. 4
2016
-
Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind, phase III study of ramucirumab (RAM) + FOLFIRI vs placebo (PBO) + FOLFIRI
Annals of Oncology, Vol. 27, pp. vi198
-
Subgroup analysis in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression
Annals of Oncology, Vol. 27, Núm. 11, pp. 2082-2089
2015
-
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study
The Lancet Oncology, Vol. 16, Núm. 5, pp. 499-508
-
Randomized trial of TAS-102 for refractory metastatic colorectal cancer
New England Journal of Medicine, Vol. 372, Núm. 20, pp. 1909-1919
-
Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer
Cancer Discovery, Vol. 5, Núm. 6, pp. 598-609